FRYE; Kelly
Patent Applications and Registrations
Patent applications and USPTO patent grants for FRYE; Kelly.The latest application filed is for "vegf antagonist formulations".
Company Profile
5.24.29
- FRYE; Kelly - Mendham NJ
- - Mendham NJ US
- Frye; Kelly - Pomona NY
Patent Activity
| Patent | Date |
|---|---|
| VEGF Antagonist Formulations App 20210393778 - DIX; Daniel B. ; et al. | 2021-12-23 |
| VEGF Antagonist Formulations App 20210393530 - DIX; Daniel B. ; et al. | 2021-12-23 |
| Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20210340220 - FURFINE; Eric ; et al. | 2021-11-04 |
| VEGF Antagonist Formulations App 20210252105 - DIX; Daniel B. ; et al. | 2021-08-19 |
| VEGF Antagonist Formulations App 20210252147 - DIX; Daniel B. ; et al. | 2021-08-19 |
| VEGF antagonist formulations suitable for intravitreal administration Grant 11,084,865 - Furfine , et al. August 10, 2 | 2021-08-10 |
| VEGF antagonist formulations suitable for intravitreal administration Grant 11,066,458 - Furfine , et al. July 20, 2 | 2021-07-20 |
| VEGF Antagonist Formulations App 20210077624 - DIX; Daniel B. ; et al. | 2021-03-18 |
| Formulations of VEG antagonist fusion proteins and method of manufacturing them Grant 10,857,231 - Dix , et al. December 8, 2 | 2020-12-08 |
| Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20200131246 - FURFINE; Eric ; et al. | 2020-04-30 |
| Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20200017572 - FURFINE; Eric ; et al. | 2020-01-16 |
| Method Of Manufacturing Vegf Antagonist Fusion Proteins App 20190388539 - DIX; Daniel B. ; et al. | 2019-12-26 |
| VEGF antagonist formulations suitable for intravitreal administration Grant 10,464,992 - Furfine , et al. No | 2019-11-05 |
| Method of manufacturing VEGF antagonist fusion proteins Grant 10,406,226 - Dix , et al. Sept | 2019-09-10 |
| VEGF antagonist formulations suitable for intravitreal administration Grant 10,400,025 - Furfine , et al. Sep | 2019-09-03 |
| Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20190031735 - FURFINE; Eric ; et al. | 2019-01-31 |
| Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20180155408 - FURFINE; Eric ; et al. | 2018-06-07 |
| VEGF antagonist formulations suitable for intravitreal administration Grant 9,914,763 - Furfine , et al. March 13, 2 | 2018-03-13 |
| Vegf Antagonist Formulations App 20170360930 - DIX; Daniel B. ; et al. | 2017-12-21 |
| VEGF specific fusion protein antagonist formulations Grant 9,636,400 - Dix , et al. May 2, 2 | 2017-05-02 |
| Vegf Antagonist Formulations App 20170073407 - DIX; Daniel B. ; et al. | 2017-03-16 |
| VEGF antagonist formulations suitable for intravitreal administration Grant 9,580,489 - Furfine , et al. February 28, 2 | 2017-02-28 |
| Stable VEGF antagonist formulations Grant 9,511,140 - Dix , et al. December 6, 2 | 2016-12-06 |
| Vegf Antagonist Formulations App 20160244504 - DIX; Daniel B. ; et al. | 2016-08-25 |
| Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20160244505 - FURFINE; Eric ; et al. | 2016-08-25 |
| Stable liquid formulations of dimer VEGF antagonists Grant 9,416,167 - Dix , et al. August 16, 2 | 2016-08-16 |
| Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20160213608 - FURFINE; Eric ; et al. | 2016-07-28 |
| Vegf Antagonist Formulations App 20160175439 - DIX; Daniel ; et al. | 2016-06-23 |
| VEGF antagonist formulations for intravitreal administration Grant 9,340,594 - Furfine , et al. May 17, 2 | 2016-05-17 |
| Vegf Antagonist Formulations App 20150079087 - DIX; Daniel ; et al. | 2015-03-19 |
| Stable liquid VEGF antagonist formulations Grant 08921316 - | 2014-12-30 |
| Stable liquid VEGF antagonist formulations Grant 8,921,316 - Dix , et al. December 30, 2 | 2014-12-30 |
| VEGF Antagonist Formulations for Intravitreal Administration App 20140323983 - FURFINE; Eric ; et al. | 2014-10-30 |
| VEGF antagonist formulations for intravitreal administration Grant 8,802,107 - Furfine , et al. August 12, 2 | 2014-08-12 |
| Stable liquid VEGF antagonist formulations Grant 8,710,004 - Dix , et al. April 29, 2 | 2014-04-29 |
| VEGF Antagonist Formulations for Intravitreal Administration App 20130274189 - FURFINE; Eric ; et al. | 2013-10-17 |
| Vegf Antagonist Formulations App 20130261056 - DIX; Daniel ; et al. | 2013-10-03 |
| VEGF antagonist formulations for intravitreal administration Grant 8,481,046 - Furfine , et al. July 9, 2 | 2013-07-09 |
| Dimer VEGF antagonist formulations Grant 8,404,638 - Dix , et al. March 26, 2 | 2013-03-26 |
| Vegf Antagonist Formulations App 20120178683 - DIX; Daniel ; et al. | 2012-07-12 |
| VEGF Antagonist Formulations App 20120101035 - Dix; Daniel ; et al. | 2012-04-26 |
| VEGF Antagonist Formulations for Intravitreal Administration App 20120087929 - FURFINE; Eric ; et al. | 2012-04-12 |
| VEGF antagonist formulations Grant 8,110,546 - Dix , et al. February 7, 2 | 2012-02-07 |
| VEGF antagonist formulations for intravitreal administration Grant 8,092,803 - Furfine , et al. January 10, 2 | 2012-01-10 |
| Vegf Antagonist Formulations For Intravitreal Administration App 20110257601 - FURFINE; Eric ; et al. | 2011-10-20 |
| Vegf Antagonist Formulations App 20100279933 - DIX; DANIEL ; et al. | 2010-11-04 |
| Lyophilized VEGF antagonist formulations for intravitreal administration Grant 7,807,164 - Furfine , et al. October 5, 2 | 2010-10-05 |
| Lyophilized VEGF Antagonist Formulations for Intravitreal Administration App 20100075903 - FURFINE; Eric ; et al. | 2010-03-25 |
| VEGF antagonist formulations suitable for intravitreal administration Grant 7,608,261 - Furfine , et al. October 27, 2 | 2009-10-27 |
| VEGF antagonist formulations suitable for intravitreal administration App 20070293432 - Furfine; Eric ; et al. | 2007-12-20 |
| VEGF antagonist formulations App 20060217311 - Dix; Daniel ; et al. | 2006-09-28 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 